Lower FY22 PDUFA Fees Realized In US FDA Recalculation For Hiring, Attrition Concerns
Executive Summary
Agency reissued user fee notice, saying fewer dollars were needed for adding staff. After concerns about process misunderstandings, agency withdrew earlier version of fee notice.
You may also be interested in...
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for NDAs including OTC switches were set to increase nearly 11% from FY2021 but could have gone even higher; a new notice will be issued but timing is unclear.
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.